Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (59)	5/17/1999 4:48:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 362

In addition, Dr. Bucalo stated that, ''We are also planning to begin Phase I/II clinical testing later this year with Spheramine(tm) for the treatment of Parkinson's disease. Preclinical results with Spheramine(tm) have been encouraging, and we believe this product may offer several advantages over other therapeutic approaches being tested for this disease.'' Anybody here believe this? This is what the 3/97 10-K said..... "Theracell's initial product candidate based on this technology is Spheramine-TM-, microcarriers coated with dopamine- producing human pigmented retinal epithelial ("HPRE") cells intended for the treatment of Parkinson's disease. Theracell anticipates clinical testing of Spheramine-TM- could begin in 1998." Has anyone seen any publications from Theracell? No? Bucalo..... are you pumping garbage while you're trying to make the business plan appear to have more viability than it has? Please provide data to support the use of Spheramine. If you can't supplement ilo, then please close the doors and burn, while waiting for Novartis, what is necessary for minimal administrative functions.